Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market Size (2024 - 2029)

Acute Bacterial Skin and Skin Structure Infection Market Analysis

The acute bacterial skin and skin structure infection (ABSSSI) Market is expected to record a CAGR of 8.7% during the forecast period.

COVID-19 impacted the global supply chain of pharmaceuticals, affecting the acute bacterial skin and skin structure infection (ABSSSI) market. In the early phases of the pandemic, the market saw a significant sales decline due to stringent lockdowns, supply chain restrictions, and manufacturing halts. However, according to the study published in Acta Medica Indonesia in January 2021, bacterial skin and skin structure infections are worsened in COVID-19 patients and lead to prolonged hospitalization, thereby boosting the market. According to a study published in the Journal of Infectious Diseases in Clinical Practice, many high-risk COVID-19 individuals are also more likely to experience severe bacterial infections, frequently requiring hospitalization. Thus, during the initial stages of the pandemic, there was a slight decline in the market's growth. The high risk of ABSSSI in COVID-19 patients led to increased adoption of therapeutics.

The rising prevalence and awareness of acute bacterial skin and skin structure infection, as well as increased R&D activities by pharmaceutical and biopharmaceutical companies to supply new products and novel treatments, contribute to the market's growth.

Two of the most common bacteria that cause acute bacterial skin and skin structure infections are Streptococcus pyogenes and Staphylococcus aureus, including methicillin-resistant S. aureus. Gram-negative bacteria, other Streptococcus species, and Enterococcus faecalis are less common causes. According to a study published in the Infection and Drug Resistance Journal in April 2022, a crucial emerging concept in the treatment of acute bacterial skin and skin structure infections was the availability of various approved agents with anti-MRSA activity. The availability of anti-MRSA drugs in the management of ABSSSI is expected to drive the market.

However, growing pipeline development activity and rising R&D expenditure by pharmaceutical and biotechnology companies, along with the approval of drugs, are anticipated to drive the market over the forecast period. For instance, as per clinicaltrials.gov, in May 2021, Ceftobiprole Medocarial under Phase III trials proved an effective treatment option for acute bacterial skin and skin structure infections. China National Medical Products Administration (NMPA) approved Zai Lab Ltd's new drug application for NUZYRA (omadacycline), a novel antibiotic with both oral and intravenous (IV) formulations, for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

Growing product launches and various activities by key market players, such as mergers and acquisitions, collaborations, and partnerships, are anticipated to drive the market. For instance, in July 2021, Melinta Therapeutics launched KIMYRSA (oritavancin), a lipoglycopeptide antibiotic that delivers a complete course of therapy for acute bacterial skin and skin structure infections (ABSSSI) in a single, one hour, 1,200 mg infusion.

Thus, the rising prevalence of ABSSSI, increasing strategies by key players, and rising R&D of therapeutics of ABSSSI are expected to boost the market over the forecast period. However, stringent regulatory policies by government bodies and patent expiration are expected to hinder the market in the future.

Acute Bacterial Skin and Skin Structure Infection Industry Segmentation

Acute bacterial skin and skin structure infection is a bacterial infection of the skin and associated tissues. The Food and Drug Administration (FDA) defines skin and skin structure infections as an acute bacterial skin and skin structure infection or ABSSSI if the infection is accompanied by redness, edema, and induration of a minimum surface area of 75 cm2, along with lymph node enlargement or systemic symptoms such as fever 38°C (100.4°F).

The acute bacterial skin and skin structure infection (ABSSSI) market is segmented by type of infection (hospital-acquired ABSSI and community-acquired ABSSI), route of administration (oral, parenteral, and topical), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.